Page last updated: 2024-11-07

ly 56110

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

LY 56110: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID160135
CHEMBL ID29669
SCHEMBL ID3274982
MeSH IDM0150182

Synonyms (22)

Synonym
nsc-626917
nsc626917
5-[bis(4-chlorophenyl)methyl]pyrimidine
{5-[bis(4-chlorophenyl)methyl]pyrimidine}
5-(bis(4-chlorophenyl)methyl)pyrimidine
NCI60_008515
ly-56110
dndi1278551
CHEMBL29669 ,
26766-37-0
5-[bis-(4-chloro-phenyl)-methyl]-pyrimidine(ly56110)
5-[bis-(4-chloro-phenyl)-methyl]-pyrimidine
bdbm50014324
ly 56110
pyrimidine, 5-(bis(4-chlorophenyl)methyl)-
ly56110
pyrimidine,5-[bis(4-chlorophenyl)methyl]-
SCHEMBL3274982
DTXSID00181282
FT-0744277
5-bis-( 4-chlorophenyl)methylpyrimidine
AKOS040748824

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Compound LY56110 was well absorbed but slowly excreted in the rat, dog, and monkey."( Disposition of the aromatase inhibitor LY56110 and associated induction and inhibition studies in rats, dogs, and monkeys.
Lindstrom, TD; Whitaker, GW, 1987
)
0.27

Dosage Studied

ExcerptRelevanceReference
" LY56110 induced hepatic cytochromes b5 and P-450 and cytochrome c reductase in rats after 14 days of oral dosing at 10 mg/kg but not in monkeys after 10 days of oral dosing at 10 mg/kg."( Disposition of the aromatase inhibitor LY56110 and associated induction and inhibition studies in rats, dogs, and monkeys.
Lindstrom, TD; Whitaker, GW, 1987
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AromataseRattus norvegicus (Norway rat)Ki0.02900.01800.02350.0290AID54065
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AromataseRattus norvegicus (Norway rat)EC50 (µMol)0.05500.05500.83504.1000AID54066; AID54068
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID54065Binding affinity for Cytochrome P450 19A11990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Mechanism and inhibition of cytochrome P-450 aromatase.
AID54068In vitro inhibition of cytochrome P450 19A1 by rat ovarian microsomes incubated with [3H]androstenedione and NADPH-generating system.1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Aromatase inhibition by 5-substituted pyrimidines and dihydropyrimidines.
AID54066In vitro Cytochrome P450 19A1 inhibition concentration to decrease aromatization of androstenedione in rat ovarian microsome1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Estrogen synthetase inhibitors. 2. Comparison of the in vitro aromatase inhibitory activity for a variety of nitrogen heterocycles substituted with diarylmethane or diarylmethanol groups.
AID673460Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID673459Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen expressing the beta- galactosidase gene infected rat L6 cells after 96 hrs2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (33.33)18.7374
1990's3 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.34 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]